Abstract: The present disclosure provides solid compositions comprising a sorbent and an active composition, as well as delivery devices comprising the solid compositions. The disclosure also provides methods of making the solid compositions, as well as methods of utilizing the solid compositions as a pest repellant and as attractant for targets.

Abstract: Disinfecting compositions containing hypochlorous acid and acetic acid are useful for treating biofilms in or on tissue, including biofilms related to wounds or other skin trauma. The compositions are useful for treating a variety of types of tissue, both on the surface on beneath the surface of tissue. Compositions are provided having various concentrations for different tissue types and infection levels. Compositions may be provided in gel form, and may include nanoparticle encapsulated molecules for controlled release.

Abstract: Methods of protecting a surface include applying an inner polymer layer onto a surface. The inner polymer layer is impregnated with a biologically active chemical substance that protects the surface from biofouling-induced chemical, biological, and bio-proliferative damage. The inner polymer layer is an epoxy polymer. An outer polymer layer is applied onto the inner polymer layer. The outer polymer layer is impregnated with a biologically active chemical substance that protects the inner polymer layer from biofouling-induced chemical, biological, and bio-proliferative damage. The outer polymer layer is selected from the group consisting of polyurethanes and fluorourethanes.

Abstract: A drug coating layer that prevents breakage of elongated drug crystals on a balloon surface while maintaining the drug crystals in an appropriate shape to act on the living body includes plural elongated bodies which are crystals of a water-insoluble drug each extending from the surface of the balloon at various lengths and angles, and a water-soluble additive layer provided in a space between an outer surface of an aggregate of the elongated bodies and the balloon surface to fill a space between the elongated bodies. The outer surface of the additive layer being located outside the aggregate, being uneven connecting a plurality of tip ends and side surfaces of the elongated bodies to each other. The tip ends of the elongated bodies slightly protrude from the additive layer, and the side surfaces and/or tip surfaces of the elongated body are exposed on the surface of the additive layer.

Abstract: Provided are modified release compositions in a solid oral dosage form comprising amisulpride in the form of an unequal mixture of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are formulations employing polymorphs of enantiomeric amisulpride.

Abstract: A method of treating, reducing, or alleviating a medical condition in a patient is disclosed herein. The method includes administering to a patient in need thereof a biocompatible drug comprising one or more antiviral medications together with one or more cell pathway inhibitors, the patient having at least one of a respiratory tract inflammatory disease, a central nervous system inflammatory disease, and vasculitis. The one or more antiviral medications preventing an attachment of viruses to cell walls, blocking a penetration of the viruses into cells, and/or inhibiting virus replication by damaging nucleic acids of the viruses. The one or more cell pathway inhibitors blocking an inflammatory response of inflamed tissue without inhibiting an immune response of the patient.

Abstract: A method of colouring an eyebrow, the method comprising: (i) contacting the eyebrow with a colouring composition comprising: (a) a dye compound; (b) an organic acid; and (c) an aromatic compound.

Abstract: Method and composition for treating or preventing a respiratory illness. The method includes administering at least one dose of a pharmaceutically acceptable fluid having a pH less than 3.0 into contact with at least one region of the respiratory tract present in a patient in need thereof. Respiratory illness that can be treated include COVID-19.

Abstract: The present invention provides novel inhibitors of cystathionin gamma synthase (CGS), their use as selective and non-selective herbicides, agricultural and non-agricultural herbicides, herbicides in integrated pest management, herbicides for gardening, clearing waste ground, clearing industrial or constructions sites, clearing railways and railway embankments, pesticide, fungicide, agricultural plant stimulant or antimicrobial agent. Also provided is a method for the control of undesired vegetation or clearing areas from the undesired vegetation comprising applying to the locus of said undesired vegetation, to the undesired plants or to a habitat thereof, a herbicidally effective amount of the compound of the present invention.

Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.

Abstract: The present application provides a microsphere in which a main agent is uniformly dispersed in a polymer matrix, wherein an average volume-based particle diameter of the microsphere is 1 ?m or more and 150 ?m or less, and a variation coefficient of area ratios in four regions is 0.35 or less, wherein the area ratios in four regions are calculated by (s/A)×100(%) wherein the four regions are prepared by preparing a cross section observation sample obtained by cutting the microsphere; observing the cross section observation sample with an electron microscope at a magnification capable of confirming the main agent in the microsphere or a higher magnification; and dividing the electron microscope observation image into four regions; and A is an area of a respective divided region, and s is a sum of cross section areas of the main agent included in the respective divided region.

Abstract: In an embodiment of the invention, a composition for treating a cell population comprises a medicant. The medicant moiety can be an illudofulvene analog. In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The affinity moiety can be an antibody, an antibody fragment, a receptor protein, a peptidic growth factor, an anti-angiogenic protein, a specific binding peptide, protease cleavable peptide, a glycopeptide, a peptide, a peptidic toxin, a protein toxin and an oligonucleotide. The affinity moiety can be covalently bound to the medicant via a linker.

Abstract: Liquid fill matrices comprising dissolved arsenic trioxide and having not more than 20% aqueous component and at least 80% nonaqueous component, wherein the components are miscible, are described as well as processes of preparing such liquid fill matrices and processing the liquid fill matrices into dosage forms including soft capsules; for the treatment of various ailments, such as cancer and GVHD.

Abstract: A method for producing mesoporous magnesium hydroxide nanoplates involving solvothermal treatment of a solution of a magnesium salt, a base, a glycol, and water is disclosed. The method does not use a surfactant or template in the solvothermal treatment. The method yields mesoporous nanoparticles of magnesium hydroxide having a plate-like morphology with a diameter of 20 nm to 100 nm, a mean pore diameter of 2 to 10 nm, a surface area of 50 to 70 m2/g, and a type-III nitrogen adsorption-desorption BET isotherm with a H3 hysteresis loop. An antibacterial composition containing the mesoporous magnesium hydroxide nanoplates is also disclosed. A method for reducing nitroaromatic compounds with a reducing agent and the mesoporous magnesium hydroxide nanoplates as a catalyst is also disclosed.

Abstract: The invention relates to a medical product for a fastening duration of at least 7 days having good skin compatibility. The medical product includes a central adhesive compartment (3) and an over-patch. The over-patch is free of active ingredients and is formed from a water-vapor-permeable back layer (1) and an adhesive polymer layer (2) that is free of active ingredients. The invention further relates to a method for the production of the foregoing medical product, and to kits of parts containing laminates of layers 1 and 2.

Abstract: Compositions and methods of using them for protecting skin, hair and nails against exposure to high energy visible light are described. The compositions can include one or more natural oils or extracts which are effective to absorb the high energy visible light at least to some degree.

Abstract: A pesticide composition, preparation method and use thereof; the composition having a synergism effect, including effective components A and B, wherein the active component A is thidiazuron, the active component B is polyglutamic acid, and the weight ratio of the component A to the component B is 1:(0.01-200).

Abstract: A fungicidal composition comprising a mixture of components (A) and (B), wherein components (A) and (B) are as defined in claim 1, and use of the compositions in agriculture or horticulture for controlling or preventing infestation of plants by phytopathogenic microorganisms, preferably fungi.

Abstract: Compositions for nail varnish, which are free or substantially free of nitrocellulose, include, in a cosmetically acceptable organic solvent: a primary film-forming agent consisting of polyvinyl butyral, a fumed silica, at least one secondary resin, at least one plasticiser, at least one colourant, which is insoluble in said solvent. The disclosure also relates to the use of the compositions for protecting and/or making-up the nails, as well as to packaged, ready-to-use items intended for the use.

Abstract: Provided is a method for treating cancer by administering to an individual who has the cancer a MAD1 peptide. The peptide can enhance the effect of a chemotherapeutic agent that is administered to the individual in combination with the peptide.